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Abstract 
Spinophilin is a scaffolding protein with modular domains that govern its interaction with a large number of 
cellular proteins. The Spinophilin gene locus is localized at chromosome 17q21, a chromosomal region 
frequently affected by genomic instability in different human tumours. The scaffolding protein interacts with the 
tumour-suppressor ARF which has suggested a role for Spinophilin in cell growth. More recently, in vitro and in 
vivo studies demonstrated that Spinophilin is a new tumour suppressor acting via the regulation of pRb. A clear 
downregulation of Spinophilin is found in several human cancer types. Moreover, Spinophilin loss is associated 
with a poor patient prognosis in carcinoma. Currently, there are controversial findings regarding a functional 
relationship between Spinophilin and p53 in cell cycle regulation and in carcinogenesis. Here we present the 
available data regarding Spinophilin function as a tumour suppressor. 
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1- Introduction 
Protein phosphatase 1 (PP1) is a widespread 
expressed phosphoSerine/phosphoThreonine PP 
involved in many cellular processes (Ceulemans 
and Bollen, 2004). There are four isoforms of PP1 
catalytic subunit (PP1c): PP1α, PP1β, PP1γ1 and 
PP1γ2, the latter two arising through alternative 
splicing (Sasaki et al., 1990). PP1c can form 
complexes with up to 50 regulatory subunits 
converting the enzyme into many different forms, 
which have distinct substrates specificities, 
restricted subcellular locations and diverse 
regulations (Cohen, 2002). In late 1990s, a novel 
PP1c binding protein that is a potent modulator of 
PP1 activity was characterized in rat brain and 
named spinophilin (Spn) (Allen et al., 1997). In the 
same time, two novel actin filament-binding 
proteins were purified from rat brain and named 
neurabin 1 and neurabin 2 (NEURal tissue-specific-
Actin-Binding proteIN), and the latter was further 
identified as Spn (Nakanishi et al., 1997). Spn is 
expressed ubiquitously while neurabin 1 is 
expressed almost exclusively in neuronal cells. Spn 
exhibits the characteristics of scaffolding proteins 
with multiple protein interaction domains (Allen et 
al., 1997; Sarrouilhe et al., 2006). Scaffolding 
proteins link signalling enzymes, substrates and 
potential effectors (such as channels, receptors) into 
a multiprotein signalling complex that may be 
anchored to the cytoskeleton. In the years after this 
discovery, the spectrum of Spn partners and 
functions has expanded but has remained mostly in 
the field of neurobiology (Sarrouilhe et al., 2006). 
Spn has been implicated in the pathophysiology of 
several central nervous system (CNS) diseases, 
among which are Parkinson's disease, schizophrenia 
and mood disorders (Law et al., 2004; Brown et al., 
2005). Spn is highly enriched at the synaptic 
membrane in dendritic spines, the site of excitatory 
neurotransmission and thus may control PP1 
functions during synaptic activity (Ouimet et al., 
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2004). Spn regulates plasticity at the postsynaptic 
density (PSD) by targeting PP1c to α-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA) and N-methyl-D-aspartic acid (NMDA) 
receptors, promoting their down regulation by 
dephosphorylation and thus regulating the 
efficiency of post-synaptic glutamatergic 
neurotransmission. Spn and neurabin1 play 
different roles in hippocampal and striatal synaptic 
plasticity. Spn is involved in long-term depression 
(LTD) but not in long-term potentiation (LTP) 
whereas neurabin 1 contributes selectively to LTP 
but not LTD (Feng et al., 2000; Allen et al., 2006; 
Wu et al., 2008). In the same way, the two 
scaffolding proteins form a functional pair of 
opposing regulators that reciprocally regulate 
signalling intensity by some seven-transmembrane 
domain receptors (Wang et al., 2007). Thus, an 
emerging notion is that Spn and neurabin 1 may 
differentially affect their target proteins and 
perform quite distinctive function in cell. 
Morphological studies have established that Spn is 
enriched at plasma membrane of cells although the 
protein is also expressed widely throughout the 
cytoplasm (Smith et al., 1999; Richman et al., 2001; 
Tsukada et al., 2003). Spn, which is expressed 
partly in the nucleus in mammalian cells, interacts 
in vitro and in vivo with the tumor-suppressor ARF 
(Alternative Reading Frame). Moreover, a role for 
Spn in cell growth was suggested, and this effect 
was enhanced by the interaction between Spn and 
ARF (Vivo et al., 2001). More recent studies 
showed that Spn is a new tumour suppressor and 
that a clear downregulation of this protein is found 
in several cancer types (Carnero, 2012). 
Furthermore, Spn loss is associated with poor 
patient prognosis in carcinomas (Sarrouilhe, 2014). 
This review aims to outline the state of knowledge 
regarding Spn function in carcinogenesis. 
2- Spinophilin structure 
The primate (homo sapiens and Callithrix jacchus) 
Spn proteins contain 815 amino acids whereas the 
rodent Spn (rattus norvegicus and mus musculus) 
have 817amino acids. These sequences are very 
similar, with few amino acids substitutions 
compared to the human sequence in C-terminus but 
the N-terminus is more variable even if the 
variability is weak (Figure 1). Consequently, few 
differences are observed when we compared these 
sequences to the human one: the rat and human Spn 
proteins share 96% sequence identity (Allen et al., 
1997; Vivo et al., 2001). In Cricetulus griseus, the 
sequence is shorter than the others: 631amino acids. 
Gene analysis and biochemical approaches have 
contributed to define in Spn a number of distinct 
modular domains. This 130 kDa protein contains 
one F-actin-, a receptor- and a PP1c- binding 
domains, a PSD95/DLG/zo-1 (PDZ) and three 
coiled-coil domains. Figure 2 provides a schematic 
diagram of the main Spn structural domains. 
In the five species of the Figure 1, the coiled-coil 
region has high identity with only one variation 
detected in Cricetulus griseus. The PDZ domain, 
the pentapeptide motif of PP1c -binding domain 
and the sextapeptide allowing the binding 
selectivity of PP1c isoforms, present the same 
identity. Moreover, the phosphoSer are conserved 
except the Ser-177 which is only detected in rat. 
Being not detected in mouse (G as in primates), 
Ser-177 is not a consequence of the rodent-specific 
high substitution rate. 
Spn has been isolated from rat brain as a protein 
interacting with F-actin (Satoh et al., 1998). Its F-
actin-binding domain determined to be amino 
acids 1-154 is both necessary and sufficient to 
mediate actin polymers binding and cross-linking. 
Nuclear Magnetic Resonance (NMR) and circular 
dichroism (CD) spectroscopy studies showed that 
Spn F-actin-binding domain is intrinsically 
unstructured and that upon binding to F-actin it 
adopts a more ordered structure (a phenomenom 
also called folding-upon-binding). Another actin 
binding property, namely a F-actin pointed end 
capping activity was recently proposed for this 
domain (Schüler and Peti, 2007). Spn, PP1c and F-
actin can form a trimeric complex in vitro. 
A receptor-interacting domain, located between 
amino acids 151-444, interacts with the third 
intracellular loop (3i) of various seven 
transmembrane domain receptors (Smith et al., 
1999; Richman et al., 2001) such as the dopamine 
D2 receptor (D2R), some subtypes of the α-
adrenergic (AR) and muscarinic-acetylcholine (m-
AchR) receptors. 
The primary PP1c-binding domain is located 
within residues 417-494 of Spn and this domain 
contains a pentapeptide motif (R-K-I-H-F) between 
amino acids 447 and 451 that is conserved in other 
PP1c regulatory subunits. A domain C-terminal to 
this canonical PP1-binding motif, located within 
amino acids 464 and 470, is essential for PP1 
isoform selectivity in vitro and for selective 
targeting in cells (Carmody et al., 2008).  
Recently, the 3-dimentional structure of the 
PP1/Spn holoenzyme was determined. Spn is an 
unstructured protein in its unbound state that 
undergoes a folding transition upon interaction with 
PP1c into a single, stable conformation. The 
scaffolding protein binds to PP1c and blocks some 
potential substrate binding sites without altering its 
active site, then didacting substrate specificity of 
the enzyme (Ragusa et al., 2010). A further study 
showed that the PP1/Spn holoenzyme is dynamic in 
solution.  
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Figure 1. Alignment of amino acid sequences of spinophilin in different species. Blast and Align programs via UniProt site 
were used. 
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Figure 2. Schematic drawing of spinophilin structure. The canonical protein phosphatase 1-binding domain is located within 
amino acids 447 and 451 in spinophilin. 
 
 
The complex adopts a significant more extended 
conformation in solution than in the crystal 
structure. This is the result of a flexible linker 
(ramino acids 490-494) between the PP1c-binding 
and the PDZ domains. The four residue flexibility 
is likely important for Spn biological role (Ragusa 
et al., 2011). 
Spn also contains a single consensus sequence in 
PDZ, amino acids 494-585 (Allen et al., 1997). The 
structure of the Spn PDZ domain has been recently 
solved by NMR spectroscopy. The PDZ domain 
directly binds to carboxy-terminal peptides derived 
from glutamatergic AMPA and NMDA receptors 
(Kelker et al., 2007). 
Sequence analysis predicted that the carboxy-
terminal region of Spn (amino acids 664-814) 
forms 3 coiled-coil domains. Neurabins were 
observed as multimeric forms in vitro and in vivo. 
Spn and neurabin 1 homo- and hetero-dimerize via 
their carboxy-terminal coiled-coil domains 
(MacMillan et al., 1999; Oliver et al., 2002). 
Consensus sequences for phosphorylation by 
several protein kinases (PK), including cAMP-
dependent PK (PKA), Ca2+/calmodulin-dependent 
PK II (CaMKII), cyclin-dependent PK5 (Cdk5), 
extracellular-signal regulated PK (ERK) and protein 
tyrosine kinases were observed in Spn. Two major 
sites of phosphorylation for PKA (Ser-177 not 
conserved in human, and Ser-94) and two others 
sites for CaMKII phosphorylation (Ser-100 and 
Ser-116) were located within and near the F-actin-
binding domain of Spn. The protein is 
phosphorylated in intact cells by PKA at Ser-94 and 
Ser-177 and by CaMKII at Ser-100 (Hsieh-Wilson 
et al., 2003; Grossman et al., 2004). Moreover, 
neurabins can be phosphorylated in vitro and in 
intact cells by Cdk5 on Ser-17 and ERK2 (MAPK1) 
on Ser-15 and Ser-205, phosphoSer-17 being 
abundant in neuronal cells (Futter et al., 2005). 
Several potential tyrosine phosphorylation sites lie 
within the coiled-coil regions, within a region 
adjacent to the PDZ domain and within the 
receptor-interacting domain. 
3- The Spinophilin interactome 
Spn interactome includes cytoskeletal molecules 
(F-actin, doublecortin, neurabin 1, Spn), enzymes 
(like PP1 and CaMKII), regulator of G-protein 
signalling protein (like RGS8), guanine nucleotide 
exchange factors (like kalirin 7), membrane 
receptors [like the α-ARs, m-AChRs, D2R, δ- and 
µ-opioid receptors (OR) and cholecystokinin (CCK) 
receptors], and other proteins like ions channels 
[The transient receptor potential canonical (TRPC), 
the type 2 ryanodine receptor (RYR2)], TGN38 and 
ARF. 
Shortly after the cloning of Spn as a novel PP1c-
binding protein, another laboratory cloned this 
protein based on its ability to bind to F-actin (Satoh 
et al., 1998).  
Recombinant Spn and neurabin 1 interacted with 
each other when co-expressed in cells. On the other 
hand, recombinant Spn was shown to form 
homodimers, trimers or tetramers by interaction 
between coiled-coil domains. Spn homomeric 
complexes are thought to contribute to its actin-
cross-linking activity (Satoh et al., 1998). 
Doublecortin (DCX) is a microtubule-associated 
protein that can induce microtubule polymerization 
and stabilize microtubules filaments. 
Immunoprecipitation experiments with brain 
extracts showed that Spn and DCX interact 
incultured cells (Tsukada et al., 2003).  
In vitro assays showed that DCX also binds to and 
bundles F-actin, suggesting that the protein cross-
links microtubules and F-actin.  
The distribution of DCX between the two 
cytoskeletons can be regulated by Spn and by 
phosphorylation of DCX and it was proposed that 
Spn could localize and enhance the binding of 
phosphorylated DCX to F-actin (Tsukada et al., 
2005). 
Several studies have shown that Spn preferentially 
binds to PP1γ1 and PP1α isoforms in brain extracts 
(MacMillan et al., 1999; Terry-Lorenzo et al., 2002; 
Carmody et al., 2004).  
GST-Spn fusion proteins containing the PP1c-
binding domain potently inhibit PP1 enzymatic 
activity in vitro (Allen et al., 1997; Colbran et al., 
2003).  
However, it was recently shown that instead of 
inhibiting PP1c directly, Spn regulated enzymatic 
activity by directing its substrate specificity 
(Ragusa et al., 2010).  
Spn can associate with the tyrosine phosphatase 
SHP-1 and the complex modulates platelet 
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activation by sequestering RGS10 and RGS18. The 
sequence surrounding the phosphorylation site 
Y398 in Spn fits a consensus ITIM sequence 
(I/V/L/SxY(p)xx(I/V/L) and forms a binding site 
for SHP1 (Ma et al., 2012). p70S6K is a mitogen-
activated PK that regulates cell survival and 
growth. p70S6K interaction with neurabin 1 
(Burnett et al., 1998) and Spn was demonstrated 
(Allen and Greengard, unpublished observation). 
The interaction implicates the PDZ domain of 
neurabins and the carboxyl-terminal five amino 
acids of the PK. CaMKII directly and indirectly 
associates with N- and C-terminal domains of Spn. 
Thus, Spn can target CaMKII to F-actin as well as 
target PP1 to CaMKII (Baucum et al., 2012). 
Regulator of G-protein signalling (RGS) proteins 
play a crucial role in the shutting off process of G-
protein-mediated responses (Ishii and Kurachi, 
2003). Spn binds to different members of the RGS 
family (Wang et al., 2005; Wang et al., 2007). For 
example, Spn binds to through the 391-545 amino 
acids of the scaffolding protein and the 6-9 amino 
acids of the N-terminus of RGS8 (Fujii et al., 
2008). 
Guanine nucleotide exchange factors (GEF) 
activate small G protein through the exchange of 
bound GDP for GTP. Several GEF were shown to 
interact with Spn. For example, Spn, through its 
carboxy-terminus containing the PDZ and coiled-
coil domains interacts with kalirin-7, the neuronal 
GEF for Rac1 (Penzes et al., 2001). 
Spn interacts with some receptors that belong to the 
superfamily of GPCRs, mainly in the CNS. Using 
the 3i loop of the D2R, Spn has been identified as a 
protein that specifically associates with the receptor 
in rat hippocampal (Smith et al., 1999). The 3i 
loops of α2A-AR, α2B-AR, and α2C-AR subtypes 
interact also with Spn (Richman et al., 2001). More 
recently, it has been shown that the α1B-AR interacts 
with Spn in vitro (Wang et al., 2005). In the 
cerebellum, Spn can bind to the M1-m-AChR 
using the receptor binding domain of the 
scaffolding protein (Fujii et al., 2008). Spn can also 
interact with the M2- and M3-m-AchRs but the 
binding ability to the M3-m-AChR seems to be 
weaker than those to the M1- and M2-m-AChR 
(Wang et al., 2007; Kurogi et al., 2009). Moreover, 
Spn binds to the 3i loop of CCKA and CCKB 
receptors (Wang et al., 2007). The receptor binding 
domain of Spn also associates with the 3i loop and 
a conserved region of the C-terminal tails of δ- and 
µ-OR (Fourla et al., 2012). Spn also interacts with 
the ionotropic NMDA and AMPA-type glutamate 
receptors. PDZ domain directly binds to GluR2-, 
GluR3- (AMPA receptor) and NR1C2'-, NR2A/B- 
and NR2C/D- (NMDA receptor) derived peptides 
(Kelker et al., 2007). 
TRPC ion channels are Ca2+ /cation selective 
channels that are highly expressed in the central 
nervous system. Spn was identified with other 
dendritic spines proteins as a protein partner of 
TRPC5 and TRPC6 channels (Goel et al., 2005). In 
cardiomyocytes, Spn targets PP1 to RYR2 via 
binding to a leucine zipper (LZ) motif of RYR2 and 
a LZ motif on Spn (amino acids 300-634) causing 
dephosphorylation and modulation of the channel 
activity (Marx et al., 2001). 
TGN38 is an integral membrane protein that 
constitutively cycles between the trans-Golgi 
network (TGN) and plasma membrane via 
endosomal intermediates. TGN38 directly interacts 
with the coiled-coil region of Spn, preferentially 
with the dimerized proteins (Stephens and Banting, 
1999). Spn has been shown to interact with the 
nuclear protein ARF in mammalian cells. The 
amino acids sequence 605-726, of the coiled-coil 
region of Spn, seems to be involved and an intact 
ARF N-terminal region (amino acids 1-65) is 
necessary for this interaction (Vivo et al., 2001). 
4- Spinophilin as a tumour 
suppressor 
The Spn gene locus is located on chromosome 17 at 
position 17q21.33, a cytogenetic area frequently 
associated with microsatellite instability and loss of 
heterozygosity (LOH) observed in different human 
tumours. This region contains a relatively high 
density of known (such as BRCA1), putative as well 
as several yet-unidentified candidate tumour 
suppressor genes located distal to BRCA1 locus. 
Thus, several studies in breast and ovarian 
carcinomas have suggested the presence of an 
unknown tumour suppressor gene in the area that 
includes the Spn locus. However, despite these 
preliminary genetic correlations, no in-depth 
analysis of the role of Spn as a tumour suppressor 
has been made. 
The Amancio Carnero laboratory from the Instituto 
de Biomedicine de Sevilla, in Spain, have 
addressed this possibility in vitro and in vivo, in 
three articles published in 2011. In the first study, 
immunohistochemical analysis of 35 human lung 
tumours at different stages and of different 
histopathological grades showed that Spn protein is 
absent in 20% and reduced in another 37% of 
tumours, compared to normal lung tissue (Molina-
Pinelo et al., 2011). The loss of Spn expression 
correlated with a less differentiated phenotype, 
higher grade and poor prognosis. Lower or null 
levels of Spn also correlated with nuclear 
accumulation of p53, and so to mutated p53 or loss 
of its wild-type activity. Moreover, loss of Spn 
increased the tumourigenic properties of p53 
deleted- or p53 mutated-lung tumour cells. The data 
of this study showed that Spn down-regulation in 
lung tumours contributes to carcinogenesis in the 
absence of p53. There are several mechanisms that 
might contribute to Spn down-regulation in 
The tumour suppressor function of the scaffolding protein spinophilin Sarrouilhe D, Ladeveze V 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(9) 696 
tumours, including miRNAs overexpression. 
miRNA106*, targeting Spn, are overexpressed in a 
small subset of patients with decreased Spn levels. 
Overexpression of miRNA106* significantly 
increased the tumorigenic properties of lung tumour 
cells. The results suggested that miRNA106* 
overexpression found in a subset of lung tumours 
might contribute to tumorigenesis through Spn 
down-regulation in the absence of p53. In a second 
study, tumour suppression by Spn was explored in 
in vivo model using genetically modified mice 
(Ferrer et al., 2011b). Spn-null (-/-) mice displayed 
decreased survival, increased the number of 
premalignant lesions in tissues such as the 
mammary ducts and early appearance of 
spontaneous tumours, such as lymphoma, when 
compared to WT littermates. In another series of 
experiments, the presence of mutant p53 activity 
(p53R172H) in the mammary glands was evaluated 
on a Spn heterozygous (+/-) or homozygous (-/-) 
background in mice. An increased number of 
premalignant lesions and of mammary carcinomas 
were observed in Spn heterozygous (+/-) or 
homozygous (-/-) mice when compared to WT 
littermates. The results confirmed the functional 
relationship between Spn and p53 in tumorigenicity 
and showed that Spn loss contributes to tumour 
progression rather than the tumour initiation. In a 
third study using mouse embryonic fibroblasts 
(MEFs), it was suggested that Spn acts as a tumour 
suppressor by the regulation of the stability of 
PP1cα, thereby regulating its activity on pRb (the 
phosphorylated form of the Retinoblastoma 
protein). This function of PP1cα has been 
associated with the growth arrest response; the 
hypophosphorylated form of Rb protein being the 
most abundant when cells are delayed in their 
growth (Ceulemans and Bollen, 2004). The ectopic 
overexpression of Spn in immortalized MEF greatly 
reduced tumour cell growth. Moreover, the absence 
of Spn (Spn(-/-) MEF) down-regulated PP1α 
activity resulting in a high level of pRb (Ferrer et 
al., 2011a). High level of proproliferative 
phosphorylated Rb leads to e2F activation, a 
compensatory ARF transcription, and consequently 
p53 activation. As they regulate the cell cycle, p53 
and ARF are both tumour suppressors, which are 
themselves regulated by MDM2 (Mouse double 
minute 2) protein shuttle between the nucleus and 
cytoplasm (Kamijo et al., 1998; Pomerantz et al., 
1998). Moreover, Sherr et al. (2005) suggested for 
the first time a p53-independent pathway via the 
ARF sumoylation. Ha et al. (2007) described ARF 
as a melanoma tumour suppressor by inducing p53-
independent senescence. Moreover, Du et al. (2011) 
demonstrated the functional roles of ERK and p21 
for ARF in p53-independent tumour suppression. 
Furthermore, in a p53-independent pathway, the 
over-expression of wild-type c-myc obviously up-
regulates the expression of p14 (ARF) (Liu et al., 
2012). Some members of the family of e2F 
transcription factors are also involved in cell cycle 
regulation; in particular E2F1 which expressions 
increase induces augmentation of ARF which can 
bind MDM2 and stabilize p53. In p53 (- / -) MEF, 
reduced levels of Spn enhanced tumorigenic 
potential of the cells. Indeed, inhibition of e2F by 
Rb being lifted, this results in cell proliferation no 
longer controlled by p53. Moreover, the absence of 
Spn contributes to genetic alterations during MEF 
immortalization, particularly p53 mutations. These 
results extend the observations made by the authors 
using a Spn-null mice model (Ferrer et al., 2011b). 
In summary, the results suggested that Spn is a new 
tumour suppressor acting via the regulation of pRb 
and which function is revealed in the absence of a 
functional p53 (Sarrouilhe and Ladeveze, 2012). 
This is, therefore, suggestive of partially redundant 
functions in their tumour suppression properties 
(Santamaría and Malumbres, 2011). The results 
also suggest that the specific outcome can be 
context-dependent. Spn loss may be beneficial by 
potentiating p53 in response to acute stress, and in 
contrast it can be deleterious under sustained 
mitogenic stress (Palmero, 2011). This feature is 
reminiscent of NIAM (Nucleolar Interaction of 
ARF and MDM2 protein) which acts through the 
same partners p53 and ARF (Tompkins et al., 
2007). 
Another Spn-interacting molecule is DCX, an actin-
binding and microtubule-binding protein that seems 
to be a tumour suppressor of glioma. When DCX is 
ectopically expressed into the DCX-deficient U87 
glioma cells, there is a marked suppression of the 
transformed phenotype. The cells manifest a 
reduced rate of growth in vitro and are arrested in 
the G2 phase of the cell cycle. Moreover, DCX-
transfected U87 glioma cells do not generate 
tumours in immunocompromised nude rats. In 
DCX-transfected U87 cells, phosphorylated DCX 
binds specifically to Spn and this interaction 
inhibits proliferation and anchorage-independent 
growth in glioma cells. In contrast, DCX-mediated 
growth repression is lost in glioma cells treated 
with siRNA to Spn and in HEK 293 (human 
embryonic kidney) Spn null cell line (Santra et al., 
2006). DCX, Spn and PP1c were found in the same 
protein complex from mouse brain extracts 
(Shmueli et al., 2006).  
DCX-mediated growth arrest in glioma cells may 
be through inactivation of PP1 activity by 
Spn/DCX interaction in the cytosol. Inhibition of 
PP1 activity is involved in two mechanistic links of 
reduction of glioma tumour-associated 
progressions: firstly, catastrophe in mitotic 
microtubule spindle that blocks mitosis; secondly, 
depolymerization of actin that inhibits glioma cell 
invasion (Santra et al., 2009).  
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Figure 3. Cellular cycle regulation by spinophilin. A. In normal cells, the presence of nuclear p53 and Spn proteins regulates 
cell cycle. The binding of PP1ca to Spn allows dephosphorylation of pRb, which inhibits E2F1 and thus the proliferation. 
Furthermore both tumour suppressors (p53 and ARF) regulate the cell cycle. The nucleolar ARF is also a partner of Spn, and 
regulates the cell cycle via Mdm2 and E2F1. B. In the case of colorectal carcinomas, Spn play a role in regulation of cell cycle 
via a p53/ARF independent pathway. One hypothesis suggested by the team of Amancio Carnero is that the Ras/Raf pathway 
could be implicated (Estevez-Garcia et al., 2013). This cytoplasmic pathway could be regulated by cytoplasmic Spn. K-Ras: 
GTPase, oncogene; B-Raf: serine/threonine protein kinase, proto-oncogene; Mek: tyrosine/threonine kinase (Mapk kinase); 
Mapk: mitogen-activated protein kinase. 
 
Moreover, double transfection with DCX and Spn 
reduced self-renewal in brain tumour stem cells via 
incomplete cell cycle endomitosis (Santra et al., 
2011). But, is there relevance for Spn as a 
prognostic marker in patients with cancer? Spn is 
absent in 20% and reduced in another 37% of 
human lung tumors (Molina-Pinelo et al., 2011). 
A further analysis of Spn in human tumours shows 
that Spn mRNA is lost in a percentage of renal 
carcinomas and lung adenocarcinomas. A clear 
down-regulation of Spn was found in tumoral 
samples of the CNS (oligodendrogliomas, 
anaplastic astrocytomas, glioblastomas) when 
compared to normal nervous samples. Furthermore, 
lower levels of Spn mRNA correlate with higher 
grade of ovarian carcinoma and chronic 
myelogenous leukemia (Carnero, 2012). Two 
articles published in spring 2013 associated Spn 
loss with poor patient prognosis in patients with 
carcinoma (Sarrouilhe, 2014). The 17q 
chromosomal region is commonly impaired in 
hepatocellular carcinoma (Furge et al., 2005). In the 
first study, complete loss of Spn immunoreactivity 
was found in 42.3% hepatocellular carcinoma and 
reduced levels were found in additional 35.6% 
cases. Quantitative RT-PCR analysis confirmed in 
70% cases a significant reduced Spn mRNA 
expression in tumour tissue compared with the 
corresponding non-neoplastic tissue. miRNA106*, 
targeting Spn in lung tumours, could not be 
detected in any of the hepatocellular carcinoma 
samples. Moreover, no correlations could be found 
for the number of Spn-positive tumour cells and 
p53 or ARF staining. These results suggested a 
p53-independent tumorigenic role of Spn in 
hepatocellular carcinoma. Disease recurrence was 
diagnosed after the 10-year follow-up in 85.2% 
cases with Spn low expression and 60.9% with Spn 
high expression. Death occurred in 76.5% cases 
with Spn low expression and in 56.5% cases with 
Spn high expression. Overall, low Spn expression is 
a factor for poor prognosis in hepatocellular 
carcinoma. In vitro experiments (human hepatoma 
cell line HepG2) and in vivo observations (Ki67-
positive tumour cells) showed that reduced Spn 
expression significantly correlated with a higher 
proliferation of liver cancer cells (Aigelsreiter et al., 
2013). 
In the second study, the role of Spn was explored in 
colorectal carcinoma, in which a number of 
chromosomal regions are altered (Fearon, 2011). 
Among them, the 17q21 is lost in a high percentage 
of this carcinoma (Garcia-Patiño et al., 1998). 
Quantitative RT-PCR analysis showed that 
approximately 25% of colorectal carcinoma 
tumours had a greater than 50% decrease in Spn 
mRNA levels compared with normal colonic tissue. 
A tissue array of human colorectal carcinomas was 
generated to confirm this result by exploring the 
presence of Spn protein. 70% of colorectal 
carcinomas displayed high Spn levels (similar to 
the values observed in normal tissue), 20% showed 
intermediate levels and 10% showed no expression 
of Spn. Moreover, Spn down-regulation correlated 
with a more aggressive histologic phenotype 
(higher Ki67-positive tumour cells) and was 
associated with faster relapse and poorer survival in 
patients with advanced stages of colorectal 
carcinoma. The data also suggested that Spn loss 
induced a chemoresistance in patients with 
advanced stages of colorectal carcinoma that had 
received adjuvant fluoropyrimidine chemotherapy 
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following surgical resection. Therefore, the 
identification of the levels of Spn in advanced 
stages of colorectal biopsies has prognostic and 
predictive value and might contribute to select 
patients who could or could not benefit from 
current chemotherapy. In vitro and in vivo 
experiments showed no functional relationship 
between Spn levels and the presence or absence of 
mutated p53 in colon cancer. The authors proposed 
that this correlation is dependent on the molecular 
context of the tumour cell (Estevez-Garcia et al., 
2013). 
5- Discussion and perspectives 
We are still only at the early stage in unravelling 
the function of Spn in cell cycle regulation. Overall, 
the different studies on the tumour suppressor 
function of Spn show two pathways of cell cycle 
regulation by Spn. The first model is a pathway 
dependent of p53 and ARF.  
This pathway was previously described in several 
articles where Spn interacts with different partners 
localized in the nucleus (Figure 3A). The second is 
a pathway independent of both molecules. As Spn 
is ubiquitously expressed in the cell, the first model 
highlights the nuclear localization of Spn and its 
interaction with other nuclear proteins.  
The second model, more hypothetical, underlines 
the possibility that Spn could interact with 
cytoplasmic partners. The studies made on 
colorectal carcinomas show that Spn could play a 
role in a pathway independent of p53/ARF. One 
hypothesis is that the Ras/Raf pathway and more 
precisely K-Ras/B-Raf is implicated. This pathway, 
via Mek (tyrosine/threonine kinase) and Mapk 
(mitogen activated protein kinase) induces 
transcription factors and proliferation survical 
(Figure 3B). 
Further studies are needed to elucidate the 
underlying mechanisms linking Spn to carcinomas 
and expand the prognostic and predictive value of 
the Spn expression level to other types of cancer. 
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